Astrazeneca

IMFINZI

Manufacturer:

Astrazeneca

Imfinzi HCPCS:

J9173

HCPCS Code Descriptor:

Injection, durvalumab, 10 mg

Category:

J Code

Imfinzi NDCs:

00310-4500-12, 00310-4611-50

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Imfinzi:

IMFINZI is an Oncology drug manufactured by Astrazeneca and administered via the Intravenous route of administration. The J Code: J9173 is aligned to the drug IMFINZI.

Imfinzi works by blocking a protein on the surface of cancer cells called PD-L1. Imfinzi is administered via intravenous infusion over a one-hour time frame. Imfinzi was previously aligned to the temporary HCPCS C9492 before receiving the permanent HCPCS J9173. Patient support for this medication can be found through the Astrazeneca Pharmaceuticals AZ & Me prescription savings program and others.

ACCESS PRICING AND MORE BY REGISTERING

J9173 Added Date:

January 1, 2019

J9173 Effective Date:

January 1, 2019

J9173 Termination Date:

HCPCS Active

Imfinzi billing and coding information can be found through Astrazeneca at the link below:
Imfinzi patient assistance information can be found through The AZ&Me Prescription Savings Program at the URL: https://www.azandmeapp.com/prescriptionsavings/
IMFINZI prescribing information can be found at the link below:
Information regarding IMFINZI’s side effects can be found at MedlinePlus